Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408063 | 0.88 | KMT2A (0.67) | KMT2AMAPK1ACECTSSCTSL | |
| SCHEMBL4900321 | 0.88 | KMT2A (0.67) | KMT2AMAPK1ACECTSSCTSL | |
| SCHEMBL6346571 | 0.87 | KMT2A (0.63) | KMT2AMAPK1ACECTSSCTSL | |
| SCHEMBL6350465 | 0.87 | KMT2A (0.66) | KMT2AMAPK1ACECTSSCTSL | |
| SCHEMBL29165165 | 0.83 | KMT2A (0.63) | KMT2AMAPK1ACECTSSCTSL | |
| SCHEMBL7544578 | 0.83 | CTSS (0.61) | KMT2AMAPK1ACECTSSCTSL | |
| SCHEMBL15545933 | 0.83 | KMT2A (0.63) | KMT2AMAPK1ACECTSSCTSL | |
| SCHEMBL3052482 | 0.82 | KMT2A (0.60) | KMT2AMAPK1ACECTSSCTSL | |
| SCHEMBL13291363 | 0.81 | KMT2A (0.64) | KMT2AMAPK1ACECTSSCTSL | |
| SCHEMBL27340724 | 0.81 | KMT2A (0.64) | KMT2AMAPK1ACECTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | KMT2A 2660/4885MAPK1 2248/4885ACE 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.